A systematic in-vitro and in-silico approaches on evaluation of commercially available Metformin Hcl tablets
Abstract
The main objectives of the investigational study are in-vitro and in-vivo evaluation of Metformin Hcl tablets on Non-Insulin Dependent Diabetic Mellitus (NIDDM). Various tablet parameters were evaluated through in-vitro tests on marketed brands of Metformin Hcl tablets. The results obtained earlier are correlated with variation in dissolution profiles the dissolution profiles of the marketed brands with regard to any possible bio-equivalence are analysed. In-silico studies are important to locate molecular targets for NIDDM. Through homology modelling and active-site prediction, the suitable protein and receptor for Metformin Hcl were identified.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.